Search Results - "TAKEZAKO, N"

Prognostic value of sequencing-based minimal residual disease detection in patients with multiple myeloma who underwent autologous stem-cell transplantation by Takamatsu, H., Takezako, N., Zheng, J., Moorhead, M., Carlton, V.E.H., Kong, K.A., Murata, R., Ito, S., Miyamoto, T., Yokoyama, K., Matsue, K., Sato, T., Kurokawa, T., Yagi, H., Terasaki, Y., Ohata, K., Matsumoto, M., Yoshida, T., Faham, M., Nakao, S.

“…Most patients with multiple myeloma (MM) are considered to be incurable, and relapse owing to minimal residual disease (MRD) is the main cause of death among…”
Get full text

Corrigendum to “Prognostic value of sequencing-based minimal residual disease detection in patients with multiple myeloma who underwent autologous stem-cell transplantation”: [Annals of Oncology 28 (2017):2503–2510] by Takamatsu, H., Takezako, N., Zheng, J., Moorhead, M., Carlton, V.E.H., Kong, K.A., Murata, R., Ito, S., Miyamoto, T., Yokoyama, K., Matsue, K., Sato, T., Kurokawa, T., Yagi, H., Terasaki, Y., Ohata, K., Matsumoto, M., Yoshida, T., Faham, M., Nakao, S.

Get full text

Trends of survival in patients with multiple myeloma in Japan: a multicenter retrospective collaborative study of the Japanese Society of Myeloma by Ozaki, S, Handa, H, Saitoh, T, Murakami, H, Itagaki, M, Asaoku, H, Suzuki, K, Isoda, A, Matsumoto, M, Sawamura, M, Konishi, J, Sunami, K, Takezako, N, Hagiwara, S, Kuroda, Y, Chou, T, Nagura, E, Shimizu, K

Get full text

Significance of Measurement of Serum Wilm’s Tumor 1 (WT1) Gene Level in Myelodysplastic Syndrome (MDS) by Kurimoto, M, Sekiguchi, N, Kurihara, Y, Ito, K, Takezako, N

Get full text

The efficacy and safety of high dose melpharan plus bortezomib followed by auto PBSCT in elderly multiple myeloma patients by Takezako, N, Sekiguchi, N, Nagata, A, Miwa, A

Get full text

Up-Regulation of TNFRSF13 and HMGB1 in Waldenstrom Macroglobulinemia with Osteolytic Bone Lesion by Sekiguchi, N, Takezako, N, Nagata, A, Fukuda, I, Yamada, K, Yoon, S.S

Get full text

Ongoing Studies/Open Questions in Asia Pacific by Ishida, T, Spencer, A, Hou, P.J, Lee, J.H, Kimura, H, Kubo, K, Sunami, K, Ozaki, S, Takezako, N, Handa, H, Kosugi, H, Murakami, H, Shimizu, K

Get full text

Revised International Staging System applied to Japanese patients: A multicenter retrospective collaborative study of the Japanese Society of Myeloma by Ozaki, S, Saitoh, T, Handa, H, Murakami, H, Suzuki, K, Takezako, N, Konishi, J, Sunami, K, Kuroda, Y, Itagaki, M, Asaoku, H, Shimizu, K, Nagura, E

Get full text

PB2019: EFFICACY AND SAFETY OF IXAZOMIB PLUS LENALIDOMIDE AND DEXAMETHASONE FOLLOWING INJECTABLE PROTEASOME INHIBITOR-BASED THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA by Sasaki, M., Suzuki, K., Abe, Y., Ito, S., Nishiwaki, K., Handa, H., Chou, T., Soeda, J., Mori, I., Shinozaki, T., Takezako, N.

Get full text

Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX by Dimopoulos, Meletios A, San-Miguel, Jesus, Belch, Andrew, White, Darrell, Benboubker, Lotfi, Cook, Gordon, Leiba, Merav, Morton, James, Ho, P Joy, Kim, Kihyun, Takezako, Naoki, Moreau, Philippe, Kaufman, Jonathan L, Sutherland, Heather J, Lalancette, Marc, Magen, Hila, Iida, Shinsuke, Kim, Jin Seok, Prince, H Miles, Cochrane, Tara, Oriol, Albert, Bahlis, Nizar J, Chari, Ajai, O' Rourke, Lisa, Wu, Kaida, Schecter, Jordan M, Casneuf, Tineke, Chiu, Christopher, Soong, David, Sasser, A Kate, Khokhar, Nushmia Z, Avet-Loiseau, Hervé, Usmani, Saad Z

“…In the POLLUX study, daratumumab plus lenalidomide/dexamethasone significantly reduced risk of progression/death versus lenalidomide/dexamethasone alone in…”
Get full text

222 - Significance of Measurement of Serum Wilm’s Tumor 1 (WT1) Gene Level in Myelodysplastic Syndrome (MDS) by Kurimoto, M., Sekiguchi, N., Kurihara, Y., Ito, K., Takezako, N.

Get full text

Simple prognostic model for patients with multiple myeloma: a single-center study in Japan by KANEKO, M, KANDA, Y, MIWA, A, TOGAWA, A, OSHIMA, K, NANNYA, Y, SUGURO, M, YAMAMOTO, R, CHIZUKA, A, HAMAKI, T, MATSUYAMA, T, TAKEZAKO, N

“…The range of survival duration in myeloma patients is wide and several percent of patients live longer than 10 years. Therefore, a precise prediction of…”
Get full text

Myopericarditis caused by cyclophosphamide used to mobilize peripheral blood stem cells in a myeloma patient with renal failure by YAMAMOTO, R, KANDA, Y, KAMI, M, MORI, S-I, KOJIMA, T, SAITO, K, ITAOKA, Y, KASHIDA, M, MATSUYAMA, T, OSHIMA, K, NANNYA, Y, SUGURO, M, CHIZUKA, A, HAMAKI, T, TAKEZAKO, N, MIWA, A

“…Cyclophosphamide (CPA) is widely used for peripheral blood stem cell mobilization, and a dose adjustment of CPA in the presence of renal failure has not been…”
Get full text

The diagnostic value of kappa/lambda ratios determined by flow cytometric analysis of biopsy specimens in B-cell lymphoma by CHIZUKA, A., KANDA, Y., NANNYA, Y., OSHIMA, K., KANEKO, M., YAMAMOTO, R., SUGURO, M., HAMAKI, T., MATSUYAMA, T., TAKEZAKO, N., MIWA, A., TOGAWA, A.

“…Flow cytometry (FC) is widely utilized in the diagnosis of lymphoma and the light chain ratio (LCR) is especially useful in the diagnosis of B‐cell malignancy…”
Get full text

Clinical Value of Serial Measurement of Serum C-Reactive Protein Level in Neutropenic Patients by Yonemori, Kan, Kanda, Yoshinobu, Yamamoto, Rie, Hamaki, Tamae, Suguro, Miyuki, Chizuka, Aki, Matsuyama, Tomohiro, Takezako, Naoki, Miwa, Akiyoshi, Togawa, Atsushi

“…C-reactive protein (CRP) is an acute phase reactant of inflammation. We evaluated the clinical value of serial measurement of CRP in neutropenic patients. CRP…”
Get full text

PB2019: EFFICACY AND SAFETY OF IXAZOMIB PLUS LENALIDOMIDE AND DEXAMETHASONE FOLLOWING INJECTABLE PROTEASOME INHIBITOR‐BASED THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA by Sasaki, M., Suzuki, K., Abe, Y., Ito, S., Nishiwaki, K., Handa, H., Chou, T., Soeda, J., Mori, I., Shinozaki, T., Takezako, N.

Get full text

Spontaneous Remission in Acute Type Adult T-Cell Leukemia/Lymphoma by Takezako, Yayoi, Kanda, Yoshinobu, Arai, Chiaki, Takezako, Naoki, Shirai, Yuko, Hirano, Naoto, Miwa, Akiyoshi, Togawa, Atsushi

“…Adult T-cell leukemia/lymphoma (ATL) is a neoplastic disorder of T lymphocytes associated with human T lymphotropic virus type I (HTLV-I). The prognosis of ATL…”
Get full text

Lack of Correlation Between Clinical Characteristics and Serum Soluble Fas Ligand Levels in Patients with Multiple Myeloma by Kanda, Yoshinobu, Arai, Chiaki, Akichizuka, Yamamoto, Rie, Hamaki, Tamae, Suguro, Miyuki, Matsuyama, Tomohiro, Takezako, Naoki, Miwa, Akiyoshi, Tohma, Junko, Shirakawa, Kamon, Yatomi, Takehiro, Nakamura, Norio, Hirai, Hisamaru, Togawa, Atsushi

“…Multiple myeloma is characterized by the accumulation of malignant plasma cells in the bone marrow and rarely cured by chemotherapy. Villunger et al. showed…”
Get full text

PB2148 POMALIDOMIDE + BORTEZOMIB + LOW‐DOSE DEXAMETHASONE IN JAPANESE PATIENTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA: A SUBGROUP ANALYSIS OF THE PHASE 3 OPTIMISMM TRIAL by Matsue, K., Sunami, K., Suzuki, K., Takezako, N., Shinagawa, A., Sakurai, S., Tamakoshi, H., Biyukov, T., Peluso, T., Richardson, P.

“…Background: The immunomodulatory agent pomalidomide (POM) in combination with dexamethasone (DEX) is approved in Japan for the treatment (Tx) of relapsed…”
Get full text

ST2 suppresses IL-6 production via the inhibition of IκB degradation induced by the LPS signal in THP-1 cells by Takezako, Naoki, Hayakawa, Morisada, Hayakawa, Hiroko, Aoki, Shinsuke, Yanagisawa, Ken, Endo, Hitoshi, Tominaga, Shin-ichi

“…LPS induces the production of inflammatory cytokines via the stimulation of Toll-like receptors. In this study, we demonstrated that a soluble secreted form of…”
Get full text